Brief: Pluristem Reports Positive Top-Line Results From Its Multinational Phase II Intermittent Claudication Study

Pluri

12/06/2018 11:06

June 12 (Reuters) - Pluristem Therapeutics Inc  PSTI.O :
    * PLURISTEM REPORTS POSITIVE TOP-LINE RESULTS FROM ITS
MULTINATIONAL PHASE II INTERMITTENT CLAUDICATION STUDY
    * PLURISTEM THERAPEUTICS INC - PLX-PAD TREATMENT REDUCED
RISK OF
REVASCULARIZATION AND IMPROVED PATIENTS' MOBILITY
    * PLURISTEM THERAPEUTICS INC - PLX-PAD TREATMENT REDUCED
RISK OF
REVASCULARIZATION AND IMPROVED PATIENTS' MOBILITY
    * PLURISTEM THERAPEUTICS INC - STUDY VALIDATES DESIGN OF
PLURISTEM'S ONGOING PIVOTAL PHASE III STUDY IN CRITICAL LIMB
ISCHEMIA (CLI)
    * PLURISTEM THERAPEUTICS INC - PLX-PAD TREATMENT REDUCED
INCIDENCE
OF REVASCULARIZATION AND IMPROVED PATIENTS' MOBILITY
    * PLURISTEM THERAPEUTICS INC - STUDY RESULTS DEMONSTRATED
DOSE OF
300 MILLION PLX-PAD CELLS AS OPTIMAL DOSE FOR TREATMENT OF PAD
    * PLURISTEM THERAPEUTICS - KEY PRIMARY EFFICACY ENDPOINT IN
ANALYSIS BY COUNTRY, SHOWED RESULTS WITH STATISTICALLY
SIGNIFICANT IMPROVEMENT IN U.S PATIENTS
    * PLURISTEM THERAPEUTICS INC - IM ADMINISTRATION OF PLX-PAD
CELLS
WAS SAFE AND WELL TOLERATED IN STUDY

Source text for Eikon:  ID:nGNX7kHN1X 
Further company coverage:  PSTI.O 

 ((Reuters.Briefs@thomsonreuters.com;))